Trial Profile
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Iobenguane (Primary) ; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide; Etoposide phosphate; Isotretinoin; Melphalan; Sargramostim; Thiotepa; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Registrational; Therapeutic Use
- 02 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results (n=360; As of December 31, 2022) assessing the preliminary feasibility and acceptability of the first COG trial to prospectively embed SDOH data collection, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 25 Apr 2023 Planned number of patients changed from 813 to 724.